Re: Inflammatory markers and the risk of Alzheimer disease: the Framingham Study.
Tobinick
Edward L
EL
D000368:Aged; D000369:Aged, 80 and over; D000544:Alzheimer Disease / Q000188:drug therapy / Q000276:immunology*; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000494:pharmacology / Q000627:therapeutic use; D015415:Biomarkers / Q000032:analysis / Q000097:blood; D001921:Brain / Q000276:immunology / Q000378:metabolism / Q000503:physiopathology; D004660:Encephalitis / Q000150:complications / Q000276:immunology*; D006801:Humans; D007963:Leukocytes, Mononuclear / Q000276:immunology* / Q000378:metabolism; D008137:Longitudinal Studies; D011237:Predictive Value of Tests; D012307:Risk Factors; D009435:Synaptic Transmission / Q000276:immunology; D016896:Treatment Outcome; D014409:Tumor Necrosis Factor-alpha / Q000378:metabolism*
D000894:Anti-Inflammatory Agents, Non-Steroidal; D015415:Biomarkers; D014409:Tumor Necrosis Factor-alpha